Lack of efficacy of interferon-α therapy in recurrent, advanced cervical cancer

S. Wadler, R. D. Burk, D. Neuberg, Robert D. Burk, C. D. Runowicz, G. Goldberg, F. McGill, R. Tachezy, R. Comis, J. Edmonson, P. H. Wiernik

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Human papillomavirus (HPV) is associated with 65-95% of in situ or early invasive squamous cell carcinomas of the cervix. A multiinstitutional, prospective phase II clinical trial was initiated by the Eastern Cooperative Oncology Group (ECOG) to study the activity of IFN-α2b in women with metastatic or locally recurrent cervix cancer. The activity of IFN-α2b was correlated with the presence of HPV as measured by Southern blot hybridization or polymerase chain reaction techniques in 17 patients. All patients had failed prior definitive therapy with surgery, radiation, and chemotherapy. IFN-α2b was administered at 10 MU/m2 subcutaneously three times per week. Among 31 patients enrolled, 3 achieved a clinical response to treatment. Tumor was accessible for biopsy in 17 patients. The presence of HPV was assayed by Southern blot hybridization (2 of 17) and/or polymerase chain reaction (PCR) technology (15 of 17). Of the 17 assays, 16 were informative. HPV was detected in 5 of 16 patients. Of 5 HPV-positive women, 2 responded to treatment, versus 1 of 11 HPV-negative women, thus not permitting reliable statistical analysis. It is concluded that IFN-α2b has only minimal activity against advanced, recurrent cervical cancer.

Original languageEnglish (US)
Pages (from-to)1011-1016
Number of pages6
JournalJournal of Interferon and Cytokine Research
Volume15
Issue number12
StatePublished - 1995

Fingerprint

Uterine Cervical Neoplasms
Interferons
Southern Blotting
Human papillomavirus 11
Therapeutics
Polymerase Chain Reaction
Phase II Clinical Trials
Cervix Uteri
Squamous Cell Carcinoma
Radiation
Technology
Biopsy
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Cell Biology

Cite this

Wadler, S., Burk, R. D., Neuberg, D., Burk, R. D., Runowicz, C. D., Goldberg, G., ... Wiernik, P. H. (1995). Lack of efficacy of interferon-α therapy in recurrent, advanced cervical cancer. Journal of Interferon and Cytokine Research, 15(12), 1011-1016.

Lack of efficacy of interferon-α therapy in recurrent, advanced cervical cancer. / Wadler, S.; Burk, R. D.; Neuberg, D.; Burk, Robert D.; Runowicz, C. D.; Goldberg, G.; McGill, F.; Tachezy, R.; Comis, R.; Edmonson, J.; Wiernik, P. H.

In: Journal of Interferon and Cytokine Research, Vol. 15, No. 12, 1995, p. 1011-1016.

Research output: Contribution to journalArticle

Wadler, S, Burk, RD, Neuberg, D, Burk, RD, Runowicz, CD, Goldberg, G, McGill, F, Tachezy, R, Comis, R, Edmonson, J & Wiernik, PH 1995, 'Lack of efficacy of interferon-α therapy in recurrent, advanced cervical cancer', Journal of Interferon and Cytokine Research, vol. 15, no. 12, pp. 1011-1016.
Wadler, S. ; Burk, R. D. ; Neuberg, D. ; Burk, Robert D. ; Runowicz, C. D. ; Goldberg, G. ; McGill, F. ; Tachezy, R. ; Comis, R. ; Edmonson, J. ; Wiernik, P. H. / Lack of efficacy of interferon-α therapy in recurrent, advanced cervical cancer. In: Journal of Interferon and Cytokine Research. 1995 ; Vol. 15, No. 12. pp. 1011-1016.
@article{189a207a8a594d7b95fe80310c06a227,
title = "Lack of efficacy of interferon-α therapy in recurrent, advanced cervical cancer",
abstract = "Human papillomavirus (HPV) is associated with 65-95{\%} of in situ or early invasive squamous cell carcinomas of the cervix. A multiinstitutional, prospective phase II clinical trial was initiated by the Eastern Cooperative Oncology Group (ECOG) to study the activity of IFN-α2b in women with metastatic or locally recurrent cervix cancer. The activity of IFN-α2b was correlated with the presence of HPV as measured by Southern blot hybridization or polymerase chain reaction techniques in 17 patients. All patients had failed prior definitive therapy with surgery, radiation, and chemotherapy. IFN-α2b was administered at 10 MU/m2 subcutaneously three times per week. Among 31 patients enrolled, 3 achieved a clinical response to treatment. Tumor was accessible for biopsy in 17 patients. The presence of HPV was assayed by Southern blot hybridization (2 of 17) and/or polymerase chain reaction (PCR) technology (15 of 17). Of the 17 assays, 16 were informative. HPV was detected in 5 of 16 patients. Of 5 HPV-positive women, 2 responded to treatment, versus 1 of 11 HPV-negative women, thus not permitting reliable statistical analysis. It is concluded that IFN-α2b has only minimal activity against advanced, recurrent cervical cancer.",
author = "S. Wadler and Burk, {R. D.} and D. Neuberg and Burk, {Robert D.} and Runowicz, {C. D.} and G. Goldberg and F. McGill and R. Tachezy and R. Comis and J. Edmonson and Wiernik, {P. H.}",
year = "1995",
language = "English (US)",
volume = "15",
pages = "1011--1016",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - Lack of efficacy of interferon-α therapy in recurrent, advanced cervical cancer

AU - Wadler, S.

AU - Burk, R. D.

AU - Neuberg, D.

AU - Burk, Robert D.

AU - Runowicz, C. D.

AU - Goldberg, G.

AU - McGill, F.

AU - Tachezy, R.

AU - Comis, R.

AU - Edmonson, J.

AU - Wiernik, P. H.

PY - 1995

Y1 - 1995

N2 - Human papillomavirus (HPV) is associated with 65-95% of in situ or early invasive squamous cell carcinomas of the cervix. A multiinstitutional, prospective phase II clinical trial was initiated by the Eastern Cooperative Oncology Group (ECOG) to study the activity of IFN-α2b in women with metastatic or locally recurrent cervix cancer. The activity of IFN-α2b was correlated with the presence of HPV as measured by Southern blot hybridization or polymerase chain reaction techniques in 17 patients. All patients had failed prior definitive therapy with surgery, radiation, and chemotherapy. IFN-α2b was administered at 10 MU/m2 subcutaneously three times per week. Among 31 patients enrolled, 3 achieved a clinical response to treatment. Tumor was accessible for biopsy in 17 patients. The presence of HPV was assayed by Southern blot hybridization (2 of 17) and/or polymerase chain reaction (PCR) technology (15 of 17). Of the 17 assays, 16 were informative. HPV was detected in 5 of 16 patients. Of 5 HPV-positive women, 2 responded to treatment, versus 1 of 11 HPV-negative women, thus not permitting reliable statistical analysis. It is concluded that IFN-α2b has only minimal activity against advanced, recurrent cervical cancer.

AB - Human papillomavirus (HPV) is associated with 65-95% of in situ or early invasive squamous cell carcinomas of the cervix. A multiinstitutional, prospective phase II clinical trial was initiated by the Eastern Cooperative Oncology Group (ECOG) to study the activity of IFN-α2b in women with metastatic or locally recurrent cervix cancer. The activity of IFN-α2b was correlated with the presence of HPV as measured by Southern blot hybridization or polymerase chain reaction techniques in 17 patients. All patients had failed prior definitive therapy with surgery, radiation, and chemotherapy. IFN-α2b was administered at 10 MU/m2 subcutaneously three times per week. Among 31 patients enrolled, 3 achieved a clinical response to treatment. Tumor was accessible for biopsy in 17 patients. The presence of HPV was assayed by Southern blot hybridization (2 of 17) and/or polymerase chain reaction (PCR) technology (15 of 17). Of the 17 assays, 16 were informative. HPV was detected in 5 of 16 patients. Of 5 HPV-positive women, 2 responded to treatment, versus 1 of 11 HPV-negative women, thus not permitting reliable statistical analysis. It is concluded that IFN-α2b has only minimal activity against advanced, recurrent cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=0029584568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029584568&partnerID=8YFLogxK

M3 - Article

C2 - 8746781

AN - SCOPUS:0029584568

VL - 15

SP - 1011

EP - 1016

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 12

ER -